Glazer Capital LLC’s TriSalus Life Sciences TLSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-963,032
Closed -$9.56M 521
2022
Q3
$9.56M Buy
963,032
+54,142
+6% +$536K 0.18% 179
2022
Q2
$8.95M Buy
908,890
+72,751
+9% +$715K 0.22% 153
2022
Q1
$8.19M Buy
836,139
+218,257
+35% +$2.15M 0.23% 122
2021
Q4
$6.11M Sell
617,882
-86,752
-12% -$862K 0.15% 189
2021
Q3
$7M Buy
704,634
+650,118
+1,193% +$6.36M 0.12% 204
2021
Q2
$529K Buy
+54,516
New +$535K 0.01% 601

Other funds holding TLSI

Glazer Capital LLC's TLSI Position: Q4 2022 in Review

Glazer Capital LLC sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 963,032 shares — an estimated $9.56M sold.

Glazer Capital LLC first reported a position in TLSI in Q2 2021 and held it in 6 quarters. The position peaked at $9.56M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Glazer Capital LLC reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Glazer Capital LLC sold 963,032 TriSalus Life Sciences shares in Q4 2022, an estimated $9.56M.
  • Glazer Capital LLC first reported a position in TriSalus Life Sciences in Q2 2021 and held it in 6 quarters.
  • Glazer Capital LLC's TriSalus Life Sciences position peaked at $9.56M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Glazer Capital LLC's 13F filing for Q4 2022, filed 14 Feb 2023.